Aspivix, the Swiss start-up innovating women’s care, focused on the development of non-traumatic and minimally invasive surgical instruments for gynecology, announces the successful closing of a Series-A financing round of over CHF 1'800'000. This Series-A-round will be used to finalize the development and support the clinical trial, of Aspivix’s first product. This device is dedicated to allowing painless placement of Intra-uterine contraceptive devices and other gynecology procedures. The round syndicate is made of 4FO (which led the financing), Zürcher Kantonalbank (ZKB) and several private investors from Business Angels Switzerland (BAS). VISCHER advises Aspivix in this transaction. The team is led by Matthias Staehelin (Corporate) with Vincent Reardon (Corporate).